Dyslipidemia in HIV-positive patients: A randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy

8Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

Abstract

Introduction: We designed a randomized, controlled prospective study aimed at comparing efficacy and tolerability of ezetimibe+ fenofibrate treatment versus pravastatin monotherapy in dyslipidemic HIV-positive (HIV+) patients treated with protease inhibitors (PIs). Methods: We consecutively enrolled 42 HIV+ dyslipidemic patients on stable PIs therapy (LDL cholesterol >130 mg/dl or triglycerides 200-500 mg/dl with non-HDL cholesterol >160 mg/dl). After basal evaluation, patients were randomized to a six-month treatment with ezetimibe 10 mg/day+fenofibrate 200 mg/day or with pravastatin 40 mg/day. Both at the basal evaluation and after the six-month treatment, the patients underwent blood tests for lipid parameters, and muscle and liver enzymes. Results: At baseline, the two groups (21 patients each) were similar with regards to gender, age, BMI, blood pressure and virologic and metabolic parameters. After the six-month therapy, total cholesterol, LDL cholesterol and non-HDL cholesterol decreased significantly (p <0.01) in both groups. high-density lipoprotein (HDL) cholesterol increased (44±10 to 53±12 mg/dl, p <0.005) and triglycerides decreased (from 265±118 mg/dl to 149±37 mg/dl, p <0.001) in the ezetimibe+fenofibrate group, whereas both parameters remained unchanged in the pravastatin group. Mean values of creatine kinase (CK), alanine aminotransferase and aspartate aminotransferase were unchanged in both groups; only one patient in the pravastatin group stopped the treatment after two months, due to increased CK. Conclusions: In dyslipidemic HIV+ patients on PI therapy, the association of ezetimibe+fenofibrate is more effective than pravastatin monotherapy in improving lipid profile and is also well tolerated. © 2014 Grandi AM et al; licensee International AIDS Society.

References Powered by Scopus

Use and abuse of HOMA modeling

4111Citations
N/AReaders
Get full text

Combination Antiretroviral Therapy and the Risk of Myocardial Infarction: The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group

1535Citations
N/AReaders
Get full text

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

925Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Evidence-based review of statin use in patients with HIV on antiretroviral therapy

42Citations
N/AReaders
Get full text

Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection

11Citations
N/AReaders
Get full text

Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis

6Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Grandi, A. M., Nicolini, E., Rizzi, L., Caputo, S., Annoni, F., Cremona, A. M., … Grossi, P. (2014). Dyslipidemia in HIV-positive patients: A randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. Journal of the International AIDS Society, 17. https://doi.org/10.7448/IAS.17.1.19004

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 29

73%

Researcher 7

18%

Professor / Associate Prof. 2

5%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 29

69%

Nursing and Health Professions 5

12%

Agricultural and Biological Sciences 5

12%

Pharmacology, Toxicology and Pharmaceut... 3

7%

Save time finding and organizing research with Mendeley

Sign up for free